These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37492587)

  • 1. AB-Amy: machine learning aided amyloidogenic risk prediction of therapeutic antibody light chains.
    Zhou Y; Huang Z; Gou Y; Liu S; Yang W; Zhang H; Dzisoo AM; Huang J
    Antib Ther; 2023 Jul; 6(3):147-156. PubMed ID: 37492587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correction: AB-Amy: machine learning aided amyloidogenic risk prediction of therapeutic antibody light chains.
    Antib Ther; 2023 Jul; 6(3):180. PubMed ID: 37492590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SSH2.0: A Better Tool for Predicting the Hydrophobic Interaction Risk of Monoclonal Antibody.
    Zhou Y; Xie S; Yang Y; Jiang L; Liu S; Li W; Abagna HB; Ning L; Huang J
    Front Genet; 2022; 13():842127. PubMed ID: 35368659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the sequence features determining amyloidosis in human antibody light chains.
    Rawat P; Prabakaran R; Kumar S; Gromiha MM
    Sci Rep; 2021 Jul; 11(1):13785. PubMed ID: 34215782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IonchanPred 2.0: A Tool to Predict Ion Channels and Their Types.
    Zhao YW; Su ZD; Yang W; Lin H; Chen W; Tang H
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28837067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contextualising the developability risk of antibodies with lambda light chains using enhanced therapeutic antibody profiling.
    Raybould MIJ; Turnbull OM; Suter A; Guloglu B; Deane CM
    Commun Biol; 2024 Jan; 7(1):62. PubMed ID: 38191620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RVMAB: Using the Relevance Vector Machine Model Combined with Average Blocks to Predict the Interactions of Proteins from Protein Sequences.
    An JY; You ZH; Meng FR; Xu SJ; Wang Y
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Separating clinical antibodies from repertoire antibodies, a path to in silico developability assessment.
    Negron C; Fang J; McPherson MJ; Stine WB; McCluskey AJ
    MAbs; 2022; 14(1):2080628. PubMed ID: 35771588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Kinetic Stability of a Full-Length Antibody Light Chain Dimer Determines whether Endoproteolysis Can Release Amyloidogenic Variable Domains.
    Morgan GJ; Kelly JW
    J Mol Biol; 2016 Oct; 428(21):4280-4297. PubMed ID: 27569045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploiting heterogeneous features to improve in silico prediction of peptide status - amyloidogenic or non-amyloidogenic.
    Nair SS; Subba Reddy NV; Hareesha KS
    BMC Bioinformatics; 2011; 12 Suppl 13(Suppl 13):S21. PubMed ID: 22373069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PVP-SVM: Sequence-Based Prediction of Phage Virion Proteins Using a Support Vector Machine.
    Manavalan B; Shin TH; Lee G
    Front Microbiol; 2018; 9():476. PubMed ID: 29616000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction and analysis of antibody amyloidogenesis from sequences.
    Liaw C; Tung CW; Ho SY
    PLoS One; 2013; 8(1):e53235. PubMed ID: 23308169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ReRF-Pred: predicting amyloidogenic regions of proteins based on their pseudo amino acid composition and tripeptide composition.
    Teng Z; Zhang Z; Tian Z; Li Y; Wang G
    BMC Bioinformatics; 2021 Nov; 22(1):545. PubMed ID: 34753427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding of nascent collagen by amyloidogenic light chains and amyloid fibrillogenesis in monolayers of human fibrocytes.
    Harris DL; King E; Ramsland PA; Edmundson AB
    J Mol Recognit; 2000; 13(4):198-212. PubMed ID: 10931557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine.
    Palladini G; Russo P; Bosoni T; Verga L; Sarais G; Lavatelli F; Nuvolone M; Obici L; Casarini S; Donadei S; Albertini R; Righetti G; Marini M; Graziani MS; Melzi D'Eril GV; Moratti R; Merlini G
    Clin Chem; 2009 Mar; 55(3):499-504. PubMed ID: 19131635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Machine learning prediction of antibody aggregation and viscosity for high concentration formulation development of protein therapeutics.
    Lai PK; Gallegos A; Mody N; Sathish HA; Trout BL
    MAbs; 2022; 14(1):2026208. PubMed ID: 35075980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DOTAD: A Database of Therapeutic Antibody Developability.
    Li W; Lin H; Huang Z; Xie S; Zhou Y; Gong R; Jiang Q; Xiang C; Huang J
    Interdiscip Sci; 2024 Mar; ():. PubMed ID: 38530613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A feature-based approach to predict hot spots in protein-DNA binding interfaces.
    Zhang S; Zhao L; Zheng CH; Xia J
    Brief Bioinform; 2020 May; 21(3):1038-1046. PubMed ID: 30957840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.
    Kazman P; Vielberg MT; Pulido Cendales MD; Hunziger L; Weber B; Hegenbart U; Zacharias M; Köhler R; Schönland S; Groll M; Buchner J
    Elife; 2020 Mar; 9():. PubMed ID: 32151314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physicochemical consequences of amino acid variations that contribute to fibril formation by immunoglobulin light chains.
    Raffen R; Dieckman LJ; Szpunar M; Wunschl C; Pokkuluri PR; Dave P; Wilkins Stevens P; Cai X; Schiffer M; Stevens FJ
    Protein Sci; 1999 Mar; 8(3):509-17. PubMed ID: 10091653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.